β-sarcoglycan Inhibitors
β-sarcoglycan inhibitors are chemical compounds that specifically target the β-sarcoglycan protein, an integral component of the sarcoglycan complex within the dystrophin-glycoprotein complex (DGC). This complex is located at the muscle cell membrane and plays a key role in maintaining the structural integrity of muscle cells. β-sarcoglycan is a transmembrane protein that interacts with other sarcoglycan subunits (α, γ, and δ) to form a tight assembly, contributing to muscle cell stability and signaling pathways. The inhibitors of β-sarcoglycan are typically designed to interfere with the function or assembly of the sarcoglycan complex, thereby altering the protein's interactions with other cellular components.
These inhibitors are important tools for researchers studying muscle cell biology, particularly in exploring the structural and mechanical properties of the sarcolemma, the outer membrane of muscle fibers. By inhibiting β-sarcoglycan, researchers can observe changes in membrane integrity, signaling cascades, and protein-protein interactions within the dystrophin-associated glycoprotein complex. β-sarcoglycan inhibitors are often used in experimental models to better understand the molecular composition and behavior of the sarcoglycan complex under different conditions. These compounds enable scientists to dissect the specific roles that β-sarcoglycan plays in maintaining the stability and functionality of muscle tissue, providing a deeper understanding of its role in muscle architecture. Through these studies, β-sarcoglycan inhibitors help elucidate the intricate details of protein complexes in muscle cells, contributing valuable insights into cellular structure and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone may downregulate β-sarcoglycan expression through interaction with glucocorticoid response elements adjacent to the SGCB gene, leading to decreased transcription. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
This compound could diminish β-sarcoglycan expression by inhibiting TGF-β signaling, which may be necessary for maintaining its expression in muscle tissue. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 could reduce β-sarcoglycan levels by blocking NF-κB, potentially a transcriptional activator of the SGCB gene in response to pro-inflammatory signals. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib might decrease β-sarcoglycan expression by obstructing PDGF receptor signaling pathways that could be upstream regulators of SGCB gene transcription. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
By inhibiting JAK2, Tyrphostin B42 (AG-490) may reduce transcriptional activation mediated by STAT proteins, potentially leading to decreased β-sarcoglycan synthesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could lead to a decrease in β-sarcoglycan expression by inhibiting PI3K and subsequently downregulating downstream AKT/mTOR signaling involved in muscle protein synthesis. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 might reduce β-sarcoglycan expression by inhibiting Wnt production and consequently reducing the Wnt/β-catenin signaling that can control muscle gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat) may decrease β-sarcoglycan expression by inhibiting histone deacetylase, resulting in tightened chromatin structure around the SGCB gene, thus hindering transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) could lead to reduced β-sarcoglycan expression by inhibiting DNA methyltransferases, potentially leading to demethylation of the SGCB gene promoter and transcriptional silencing. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin (Sirolimus) may inhibit β-sarcoglycan expression by targeting mTOR, a key factor in the PI3K/AKT/mTOR pathway, resulting in decreased protein synthesis capacity. | ||||||